AKT1 and breast carcinoma: Mechanically, circCDYL2 stabilizes GRB7 by preventing its ubiquitinated degradation and enhances its interaction with FAK, thereby maintaining downstream AKT and ERK1/2 activity to support trastuzumab resistance in breast cancer cells.